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The burden of the rheumatic diseases in the general adult population of Greece:
the ESORDIG study
Abstract
OBJECTIVE: To estimate the burden of rheumatic diseases in terms of disability and health-care
utilization in the Greek general adult population. METHODS: The study was conducted on the total adult
population of seven communities (8547 subjects), as well as on 2100 out of 5686 randomly selected
subjects in an additional two communities. Rheumatologists visited the participants at their homes to
assess the prevalence of six morbidity indicators concerning disability and health-care utilization
associated with rheumatic diseases or other major disease groups. RESULTS: The participation rate in the
study was 82.1%. The prevalence of chronic health problems, long-term disability, short-term disability,
physician office visits and prescription or non-prescription drug use due to rheumatic diseases in the total
target adult population was 14.3, 4.3, 2.9, 2.8, 7.2 and 2.0%, respectively. Compared with all other major
disease groups, rheumatic diseases were the most common cause of chronic health problems (38.7%),
long-term disability (47.2%), short-term disability (26.2%) and physician office visits (20.5%), while they
ranked second for the use of prescription (24.0%) or non-prescription drugs (17.7%). Rheumatic diseases
were the main cause of morbidity in five out of six indicators in subjects aged < or =65 yr. Logistic
regression analysis revealed an association of female gender, age > or =45 yr and obesity with almost all
morbidity indicators related to rheumatic diseases. CONCLUSION: These findings suggest that rheumatic
diseases constitute a major public health problem and should be considered in planning undergraduate
and postgraduate medical education, research and health-care services.
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Systemic levels of interleukin-6 and matrix
metalloproteinase-9 in patients with multiple myeloma
may be useful as prognostic indexes of bone disease

Aikaterini Sfiridaki1, Spiros Miyakis2, George
Tsirakis3, Athanassios Alegakis4, Andreas M.
Passam1, Ermioni Kandidaki1, Andrew N.
Margioris5 and Michael G. Alexandrakis3,*
1

Blood Bank Center, Venizelion General Hospital
Heraklion, Crete, Greece
2
Third Department of Medicine, University of
Athens, Greece
3
Department of Haematology, University Hospital of
Heraklion, Crete, Greece
4
Department of Biostatistics,
5
Department of Clinical Chemistry-Biochemistry,
School of Medicine, University of Crete, Heraklion,
Greece

Abstract
Multiple myeloma is characterized by accelerated production of the proteolytic enzyme matrix metalloproteinase (MMP)-9. We hypothesized that myeloma-produced MMP-9 may influence the rate of bone
turnover in a paracrine manner. Thus, we examined
the correlations of MMP-9 levels, disease severity,
and bone turnover rate as evaluated by markers of
bone formation and resorption.
Thirty-seven newly diagnosed multiple myeloma
patients (nine of Durie-Salmon stage I, 12 of stage II
and 16 of stage III) and 12 age-matched controls were
studied. Serum MMP-9 levels were significantly higher at stage II compared to stage I (188.78"91.27 vs.
59.25"33.09 ng/mL, p-0.004). Additionally, free
urine pyridinolines (F-Pyd), free urine deoxy-pyridinolines (F-Dpd) and urine N-telopeptide fragment
(NTx) were elevated, their level correlating with disease stage (p-0.001, p-0.03, p-0.001, respectively),
as were bone marrow infiltration and serum interleukin-6 (IL-6) levels (p-0.0001, p-0.01, respectively).
MMP-9 levels were lower in patients compared with
controls (p-0.001), whereas IL-6 and bone resorption
marker levels were higher in patients than in controls
(p-0.001 in all cases). Significant correlation was
found between infiltration, MMP-9, free urine pyd,
free urine dpd and NTx for each stage of the disease
(p-0.03, p-0.003, p-0.002, p-0.003 and p-0.001,
respectively). Levels of MMP-9 and of IL-6 in multiple
*Corresponding author: Michael G. Alexandrakis, Assistant
Professor of Medicine, Department of Haematology,
University Hospital of Heraklion, P.O. Box 1352, Heraklion,
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myeloma
correlate
well
with
bone
turnover rate and may be useful in disease evaluation.
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Introduction
Multiple myeloma (MM) is a malignant monoclonal
proliferation of bone marrow plasma cells, with
debilitating skeletal involvement (1, 2). Skeletal morbidity in MM correlates well with the degree of plasma cell infiltration (3, 4). The progression of the
disease involves the production by the tumor cells
of a specific class of extracellular matrix-degrading
metalloenzymes, including matrix metalloproteinase
(MMP)-9, a 92-kDa type IV collagenase (5, 6). MMP-9
degrades collagen IV, the major constituent of basement membrane, and this appears an essential step
for cellular invasion and tumor progression (7–9). The
pathogenesis of myeloma-induced bone disease is
associated with accelerated bone turnover, leading to
an imbalance between bone formation and resorption
(10). MMP-9 is predominantly expressed in cells of
macrophage lineage, such as osteoclasts that use it
to hydrolyze bone collagen type I (11, 12). It is postulated that myeloma cell-derived MMP-9 – produced
in the vicinity of bones – may enhance organic bone
matrix absorption in a direct, paracrine fashion (7, 13).
Malignant plasma cell infiltration has been shown to
be directly responsible for the increased resorptive
activity and abnormal remodeling, either by locally
produced autocrine or paracrine osteoclast-activating
factors or by direct cell to cell contact (1). Furthermore, the production of MMP-9 by myeloma cells
could be accelerated locally by cytokines, chemokines
and growth factors produced by bone cells, aggravating, thus, the invasive behavior of the malignant cells,
by the establishment of a local self-accelerating cycle
(14). Indeed, bone marrow endothelial cells were
found to enhance MMP-9 production in MM, indicating that endothelial cells accelerate MM cell invasion
via MMP-9 secretion (7, 13, 15). Bone formation and
resorption markers represent sensitive indices of the
rate of bone turnover (16–18). The aim of the present
work was to examine the levels of MMP-9 in patients
with MM and age-matched controls, and correlate
them to the severity of disease, as well as to the rate
of bone turnover. For this purpose, we measured
MMP-9 levels and bone resorption biochemical indi-
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ces in our patients, and correlated them with the
stage of their disease.

Materials and methods
Patients
The study population included 37 newly diagnosed patients
with MM: nine in stage I, 12 in stage II and 16 in stage III
according to Durie-Salmon classification (19). Serum samples from 12 persons, age- and sex-matched healthy volunteers, were used as controls. Informed consent for the study
was obtained from all subjects.
The median age of the patient group was 63 years (range
39–84 years). There were 17 males (age 39–81 years) and 20
females (age 39–81 years). Monoclonal immunoglobulins
IgG, IgA and light chain disease were found in 22, 11 and
four patients, respectively. No patient had received chemotherapy or radiotherapy prior to initial sampling. None of the
patients had evidence of thyroid or parathyroid hormonerelated abnormalities or had received any therapy known to
affect bone metabolism. According to standard X-ray evaluation of the patients, bone involvement was graded into
four scores: no lesions (score 0), one bone involved or diffuse osteoporosis (score 1), more than one but less than four
bone lesions (score 2) and more than four bone lesions or
bone fracture present (score 3). Using these definitions, 11
patients had score 0, four had score 1, six had score 2, and
16 patients had score 3.

Methods
Serum samples were collected from patients and controls,
aliquoted into separate vials and stored at y708C after collection, and assayed at the end of the study, in order to avoid
inter-assay variability.
Urinary N-telopeptide (NTx) cross-links of type I collagen
were measured by a competitive-inhibition enzyme-linked
immunosorbent assay (ELISA) (Osteomark Ostex International, Seattle, WA, USA), using a monoclonal antibody
for NTx labeled with horseradish peroxidase. Results were
collected for 24-h urinary concentration of creatinine and
expressed as nanomoles of bone collagen equivalent per
millimole of creatinine (nmol BCE/mM creat). Free urine pyridinolines (F-Pyd) were measured by a competitive enzyme
immunoassay (METRA PYD EIA assay, Metra biosystems,
Mountain View, CA, USA) using monoclonal antibodies. Free
urine deoxy-pyridinolines (F-Dpd) alone were measured by

METRA DPD EIA assay (Metra biosystems). Results for F-Pyd
and F-Dpd alone were corrected for 24-h urinary concentration of creatinine and expressed as nanomoles per millimole
of creatinine.
Measurements of IL-6 and MMP-9 in serum samples collected from patients and controls were performed by solidphase sandwich ELISA with commercially available test kits,
Quantikine Human MMP-9 (total) and IL-6 (R&D Systems
Inc., Minneapolis, MN, USA).
Bone marrow cellularity and percentage of bone marrow
infiltration by myeloma cells was estimated by bone marrow
biopsies that were taken during local anesthesia from a point
below the iliac crest.

Statistical analysis
Results are expressed as mean"SD. The non-parametric Kruskal-Wallis test and one-way analysis of variance
(ANOVA) were assessed to test the existence of differences
between different stages. The Student-Newman-Keuls test
was used for pairwise comparison of subgroups. Statistical
comparisons between the MM group and the control group
were made using the non-parametric Mann-Whitney test.
Correlations between the various measured parameters
were calculated by Spearman’s rank correlation coefficient.
p-Values -0.05 were considered to be statistically significant.

Results
The mean concentration of IL-6 in the entire group of
patients was 6.69"5.51 pg/mL and was significantly
higher in comparison to that found in the control
group (p-0.001) (Table 1). The mean values for infiltration and IL-6 in the group of MM patients were significantly higher with increasing stage of disease
(p-0.001, p-0.01, respectively) (Table 1). Subsequently, we evaluated the measured parameters of
disease activity, infiltration and IL-6 according to the
grade of bone disease. Bone marrow infiltration was
significantly higher in grade 3 than in grade 0
(51.88"21.28 vs. 28"16.28, ps0.02). In contrast,
mean serum levels of IL-6 were higher with advancing
bone disease, but without statistical significance.
The mean concentrations of NTx, F-Pyd and F-Dpd
were significantly higher in MM patients in comparison to those found in the group of controls (p-0.001

Table 1 Values of plasma cell infiltration, IL-6, MMP-9, and of biochemical markers of bone resorption in 37 untreated MM
patients according to disease stage, and in controls. With the exception of MMP-9, values of all measured parameters were
significantly higher in MM patients than in controls. Values for infiltration, IL-6, and urinary N-telopeptide (NTx) were significantly higher with advancing stage of the disease.
Multiple myeloma group

Infiltration
IL-6, pg/mL
MMP-9, ng/mL
NTx
F-Pyd
F-Dpd

Controls

Stage I
Mean ("SD)

Stage II
Mean ("SD)

Stage III
Mean ("SD)

22.56"16.09
3.06"1.33
59.25"33.09
86"67.49
26.6"6.5
5.7"1.6

33.58"19.78
5.71"3.48
188.78"91.27***
159"61.23
54.3"19.6**
12.3"5.3***

56.25"16.78*
9.47"6.79**
131.2"96.32
222.4"47.68*
58.4"23.8*
11.9"5.3***

0.98"0.64q
289.8"110.46q
32.67"3.11q
20.83"2.62*
4.17"0.72q

*Stage III vs. I and II p-0.001, **Stage III vs. I p-0.002, ***Stage II vs. I p-0.004, qcontrol group vs. multiple myeloma group
p-0.001.
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Figure 1 Correlation between serum MMP-9 levels and urinary N-telopeptide (NTx) values in 37 newly diagnosed multiple myeloma patients. A significant positive correlation was
found between serum MMP-9 and NTx values (Spearman’s
correlation coefficient, rs0.340, p-0.04).

were higher in grade 3 compared to grade 0
(61.81"22.17 vs. 30.55"15.91, p-0.002, and 13.13"
5.46 vs. 6.27"2.72, p-0.003, respectively). In contrast, the mean concentrations of F-Pyd and F-Dpd in
grades 0, 1 and 2 were increasing gradually with
advancing bone disease, but differences did not reach
statistical significance. Moreover, mean concentrations of NTx were higher in grade 3 compared to
grades 0, 1 and 2 (p-0.001 in all cases).
We further evaluated the levels of MMP-9 in healthy
controls and in the group of patients. The mean
serum concentration of MMP-9 (132.37"95.14 ng/mL)
was lower in the group of patients compared to the
control group (289.80"110.46 ng/mL, p-0.001)
(Table 1). Furthermore, MMP-9 mean serum concentration was significantly higher in stage II, in comparison to stage I (p-0.004). Stratification of MMP-9
serum levels according to the grade of bone disease
revealed higher levels in grade 2 vs. grades 0 and 1
(p-0.003, p-0.02, respectively). Of note, a positive
correlation was found between infiltration and NTx
levels (rs0.340, p-0.03) as well as between serum
IL-6 and NTx levels (rs0.340, p-0.04). A significant
correlation was found between serum MMP-9 and
NTx values (rs0.340, p-0.04) (Figure 1). In addition,
a trend was detected between MMP-9 values and
F-Pyd and F-Dpd, which approached statistical significance (rs0.299, ps0.07 and rs0.228, ps0.08,
respectively) (Figures 2 and 3).

Discussion
We and others have shown that there is an enhancement of osteoclastic activity in MM patients (3, 4, 20).
This process is mediated by factors produced locally
by malignant and non-malignant cells in the microenvironment of bones. We have found that MMP-9

Figure 2 Serum MMP-9 levels and free urine pyridinoline
(F-Pyd) values in 37 newly diagnosed multiple myeloma
patients. There was a positive correlation between serum
MMP-9 and F-Pyd values, which did not reach statistical significance (Spearman’s correlation coefficient, rs0.299,
ps0.07).

in all cases) (Table 1). In the group of MM patients,
the
mean
concentrations
of
NTx,
F-Pyd
and F-Dpd were significantly higher as the stage of
disease advanced (p-0.001, p-0.001, p-0.003, respectively).
The biochemical parameters were analyzed according to the severity of bone disease at diagnosis, as
estimated by radiographs of the whole skeleton
(grade 0 to 3). Patients with progressive bone disease
had elevated levels of F-Pyd and F-Dpd in comparison
to patients without osteolytic lesions. More specifically, the mean concentrations of F-Pyd and F-Dpd

Figure 3 Serum MMP-9 levels and free urine deoxy-pyridinoline (F-Dpd) values in 37 newly diagnosed multiple myeloma patients. There was a positive correlation between
serum MMP-9 and F-Dpd values, which did not reach statistical significance (Spearman’s correlation coefficient,
rs0.228, ps0.08).
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may play an important role in worsening bone disease in patients with MM.
In the present study, serum levels of MMP-9 in stages II and III MM patients were higher than in stage I
patients, but serum MMP-9 levels in the whole patient
group were lower compared to the age-matched control group. The explanation for this discrepancy
remains unclear. In MM patients, reduced MMP-9 levels have been detected in tumors with elevated levels
of syndecan-1 (21), however, decreased MMP-9 does
not result from association with syndecan-1 expression in malignant cells (22). Lower MMP-9 levels in
myeloma patients may be due to a reduction in MMP9 production from normal sources in MM, which leads
to a net decrease in serum MMP-9 (21). It has been
postulated that the predominant sources of serum
MMP-9 activity in normal people are the circulating
lymphocytes, neutrophils and monocytes in which
MMP-9 is thought to play an important physiological
role (23). As such cells may be crowded by malignant
plasma cells in MM, future relevant studies of MMP-9
levels from the bone lesions may help clarify this
issue. From this point of view, mast cells may also be
important as they have been reported to produce
MMP-9 (24), and mast cell chymase activates proMMP-9 (25). Mast cell release of MMP-9 and other
lytic enzymes has been associated with tumor progression and aggressiveness (26).
The progression of the disease in MM patients is
accompanied by an accelerated angiogenesis and
production of proteolytic enzymes (6, 27). Furthermore, the growth of myeloma cells is regulated by a
cytokine network in which IL-6 represents a major
growth player. We found higher serum MMP-9 levels
in patients with bone disease scores 2 and 3, in comparison to scores 0 and 1. This observation suggests
that the excessive MMP-9 activity in bone marrow
plays a functional role in pathological conditions
associated with MM, such as tumor progression and
osteolysis.
We found that the levels of serum MMP-9 correlated significantly to the estimated rate of bone turnover. Indeed, we report a positive correlation between
urinary levels of NTx, MMP-9 (rs0.328, p-0.04) and
IL-6 (rs0.340, p-0.04). Based on this finding, we and
others postulate that the accelerated bone turnover is
a result of locally produced factors (including MMP-9)
in the microenvironment of the bone, which either
accelerate bone turnover (3) or enhance their biological effect via MMP-9. In fact, our results show a trend
for direct association of MMP-9 values with F-Pyd and
F-Dpd suggesting the possible role of MMP-9, produced locally by myeloma cells, in the promotion of
osteolytic bone disease. Published reports suggest
that MMP-9 plays an important role in bone resorption (7, 16), and that MMP-9 production by plasma
cells accelerates invasiveness and angiogenesis (28).
The latter is related to the proliferative activity of
malignant plasma cells, according to our previous
results (29).
In the present study, serum levels of IL-6 correlated
well with urinary levels of NTx, and also, in contrast

with MMP-9, with disease stage, being significantly
higher in MM patients than in controls, confirming
previous results (29). Measurement, thus, of IL-6 may
provide a useful marker for monitoring disease activity in MM. Interestingly, serum IL-6 levels have been
reported to correlate well with bone involvement in
systemic mastocytosis patients (30).
We have found that the mean concentrations of
NTx, F-Pyd and F-Dpd were significantly higher in the
MM patients compared to age-matched healthy controls (p-0.001). Moreover, in the group of MM
patients the mean concentrations of NTx, F-Pyd and
F-Dpd were increasing significantly as the disease
progressed
(p-0.001,
p-0.001,
p-0.003,
respectively).
Finally, biochemical parameters were found to correlate to the severity of bone disease at diagnosis, as
estimated by X-rays. Thus, patients with progressive
bone disease had elevated levels of F-Pyd and F-Dpd
compared to patients without osteolytic lesions. Specifically, mean concentrations of F-Pyd and F-Dpd
were higher in grade 3 than in grade 0 (61.81"22.17
vs. 30.55"15.91, p-0.002, and 13.13"5.46 vs.
6.27"2.72, p-0.003, respectively).
In conclusion, we have found that levels of MMP-9
and of IL-6 in the circulation of patients with MM correlate with both the radiological disease score and the
rate of bone turnover as judged by biochemical markers of bone resorption and formation. Based on these
findings, we propose measuring the levels of MMP-9
in the blood of patients with MM, since this determination may add information regarding the severity of
their disease and the degree of its effect on bone well
being.
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